לוח שנה משולב

On Wednesday, November 16th, we will be hosting a basic user seminar given by Dr. Gerhard Heinzmann a support specialist that is installing the new technology in the Protein Analysis Unit at LSCF.

The training session will take place in the Ullmann Building, Aharon Katzir Hall, from 9:00 AM – 11:00 AM [16/11]. It includes and introduction to FFF technology and basic tools for starting to work.

If you have any further questions regarding this training session, please contact Dana:
dana@golik.co.il
054-2565007

We show that the relaxion generically stops its rolling at a point that breaks CP leading to relaxion-Higgs mixing. This opens the door to a variety of observational probes since the possible relaxion mass span a broad range from sub-eV to GeV scale. We derive constraints from current experiments (fifth force, astrophysical and cosmological probes, beam dump, flavour, LEP and LHC) and present projections from future experiments such as NA62, SHiP and PIXIE. We find that a large region of the parameter space is already under the experimental scrutiny. All the experimental constraints we derive are equally applicable for general Higgs portal models. On the theoretical side we present a new bound on the back-reaction scale, Lambda^4_{br} < m_h^2 v^2. In addition, we show that simple multiaxion (clockwork) UV completions, suffer from a mild fine tuning problem, which increases with the number of sites. These results favour a cut-off scale lower than the existing theoretical bounds.

arXiv:1610.07962 (hep-ph)

Modern Genetics is revealing virtually all the genetic and epigenetic alterations associated with human malignancies. Mining this information for Precision Medicine is predicated on weeding out ‘bystander’ mutation and identifying the ‘driver’ mutations responsible for tumor initiation, progression and metastasis, as only the latter have diagnostic and therapeutic value. Secondly, we have to elucidate how driver mutations alter the fundamental molecular pathways governing tissue growth and identify actionable nodes within a given cancer gene network that can be exploited therapeutically.
The massive quantity of data emerging from cancer genomics therefore demands a corresponding increase in the efficiency and throughput of in vivo models to comprehensively assess all putative cancer genes. We therefore developed a versatile functional genomics toolbox that enables us to generate and analyze thousands of somatic gene knock-out or overexpression clones within a single animal in a matter of weeks. Ultrasound-guided in utero injections allow us to selectively transduce fluorescently-labeled lentiviral CRISPR or ORF libraries into various organs of living mouse embryos. Subsequent mosaic analysis, next-generation sequencing and library barcode deconvolution enables us to identify genes that regulate proliferation, differentiation and survival. Of note, this analysis not only assess the gene function in an physiological and immune-competent microenvironment, but can also be combined with any mouse model and treatment schedule to faithfully model human malignancies.
Using this technique, we have completed several proof-of-concept screens and elucidated several novel tumor suppressor genes in Head&Neck. Currently, we are performing several multiplexed in vivo CRISPR screens to uncover context-specific cancer vulnerabilities, novel immune regulators and genes that confer resistance to chemo- or targeted therapies. In this seminar, I will highlight the utility of direct in vivo screening to integrate human cancer genomics and mouse modeling for rapid and systematic discovery of cancer driver mutations and novel cancer vulnerabilities.